注目 FierceBiotech 2026年4月20日 Agenus focuses on survival data as 0% response rate triggers primary miss Agenus focuses on survival data as 0% response rate triggers primary miss 開く 関連シグナル FierceBiotech 2026年4月20日 Odyssey charts fresh voyage to public markets after abandoning IPO plans last year FierceBiotech 2026年4月20日 AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win FierceBiotech 2026年4月20日 How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients